Heart failure and transplantation with Dr Ileana Piña

 
 

Heart failure and transplantation with Dr Ileana Piña

  • Predicting HF Worsening: Speech Analysis Beats Weighing Scales   Heart failure experts, Ileana Piña and Bill Abraham, discuss the HearO study on the use of AI for detecting congestion remotely and other tips and tricks they have learned over the years.
  • Quick, Reliable Marker to PUSH Decongestive Therapy in AHF   Ileana Piña and Wilfried Mullens discuss the PUSH-AHF trial on a spot urine sodium protocolized approach to decongestion presented at the European Society of Cardiology.
  • SGLT2i in Acute Heart Failure, The Earlier The Better?   Ileana Piña interviews Zachary Cox, PharmD, about the DICTATE-AHF trial on the initiation of the SGLT2 inhibitor, dapagliflozin, early in acute heart failure decompensation.
  • Heart Failure Guidelines Update: What the ESC Got Right   Heart failure specialist Dr Ileana Piña discusses what she likes about the 2023 ESC focused update to the heart failure guidelines.
  • GLP-1 Agonists in HFpEF With Obesity: Are We There Yet?   Obesity, a driver of inflammation, is prevalent in patients with HFpEF. Ileana Pina asks Ambarish Pandey about GLP-1 agonists and SGLT2 inhibitors in HFpEF. Are these drugs anti-inflammatory?
  • ACC HFpEF Guidance: What to Know   Ileana Piña, MD, MPH, discusses the Expert Consensus Decision Pathway from ACC focused on the definition, diagnosis, and treatment of heart failure with preserved ejection fraction.
  • Defining Heart Failure: EF Slicing and Dicing   Ileana L. Piña, MD, MPH, discusses the definition of heart failure based on various ejection fraction ranges and changes.
  • Clues to How SGLT2 Inhibitors Work: CAMEO-DAPA   Ileana Piña, MD, MPH, and Barry A. Borlaug, MD, discuss the CAMEO-DAPA study in patients with HFpEF and potential mechanisms of action for SGLT2 inhibitors.
  • STRONG-HF: This Is the Science, Let's Get It Done   Ileana L. Piña, MD, MPH, discusses the need to implement the findings of STRONG-HF in heart failure clinics across the globe.
  • A 'Game Changer' for Heart Transplant?   Dr DeVore, from the first US center to perform an adult heart transplant using an organ donated after circulatory death, explains the differences and similarities with brain-dead donation to Dr Piña.
  • AHA 2022 Is Finding and Fixing Iron Deficiency in HF Beneficial?   Ileana Piña interviews Paul Kalra about the IRONMAN trial from the American Heart Association which randomized HF patients with iron deficiency to IV ferric derisomaltose repletion or no infusions.
  • AHA 2022 STRONG-HF Strategy for Intense ADHF Discharge Care Explained   Alexandre Mebazaa gives Ileana Piña the details on the STRONG-HF trial that showed benefits for early intensive drug therapy after hospitalization for acute decompensated heart failure.
  • AHA 2022 Meds and Community Over Mindfulness for Most Hypertension   Catch up on blood pressure presentations from the 2022 American Heart Association meeting, including ones on mindfulness, community approaches, and a comparison of hydrochlorothiazide and chlorthalidone.
  • ESC 2022 DELIVERing the Details on Dapagliflozin in Heart Failure   Drs Pina and Solomon discuss the DELIVER trial presented at the European Society of Cardiology and whether all patients with heart failure should get SGLT2 inhibitors regardless of ejection fraction.
  • The Pig Heart Transplant Surgeon on What He Learned   Ileana Piña speaks with Bart Griffith about the first porcine-to-human cardiac xenotransplantation and where the field is going.
  • Key Points From the New Heart Failure Guidelines   Dr Ileana Piña discusses the 2022 AHA/ACC/HFSA heart failure guidelines and how they compare with the European guidelines and recent data on heart failure.
  • ACC 2022 SODIUM-HF Simplifies Message to Patients on Diet   Drs Ileana Piña and Justin Ezekowitz discuss results from the SODIUM-HF trial, which investigated the effects of a pragmatic intervention to reduce dietary sodium intake in patients with heart failure.
  • Is It Time to Redefine Iron Deficiency?   Ileana Piña was intrigued by a paper questioning whether the definitions of iron deficiency used in HF trials and guidelines are the best ones.
  • AHA 2021 CHIEF-HF: No-Touch Initiation of Canagliflozin Improves QoL   Ileana Piña and Eldrin Lewis discuss a novel, all-virtual trial of the SGLT2 inhibitor canagliflozin in patients with heart failure.
  • ESC 2021 Heart Failure Drug Management Tips and Tricks   Drs Ileana Piña and Carolyn Lam discuss how they juggle all the drugs indicated for patients with heart failure.